Lexeo Therapeutics
LXEO
31 hedge funds and large institutions have $217M invested in Lexeo Therapeutics in 2023 Q4 according to their latest regulatory filings, with 31 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
60.73% more ownership
Funds ownership: 0% → 60.73% (+61%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$37.3M |
| 2 |
DCP
D1 Capital Partners
New York
|
+$31.1M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$29M |
| 4 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
+$26.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$25.9M |
Top Sellers
LXEO Hedge Fund Activity: Q4 2023 in Review
31 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Lexeo Therapeutics (LXEO) for Q4 2023, worth a combined $217M.
Buyers outnumbered sellers: 31 funds opened new LXEO positions and 0 closed out — a net gain of 31 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Eventide Asset Management, opening a new position worth an estimated $37.3M.
- 31 institutional investors held Lexeo Therapeutics (LXEO) as of Q4 2023, up from 0 in Q3 2023.
- Funds reported $217M of Lexeo Therapeutics stock for Q4 2023.
- 31 funds opened new Lexeo Therapeutics positions in Q4 2023 and 0 closed out, a net change of +31 holders.
- The largest Lexeo Therapeutics buyer in Q4 2023 was Eventide Asset Management, an estimated $37.3M added.
Based on aggregated 13F filings for Q4 2023.